CA2494963A1 - Epitopes de lymphocytes t dans l'erythropoietine - Google Patents

Epitopes de lymphocytes t dans l'erythropoietine Download PDF

Info

Publication number
CA2494963A1
CA2494963A1 CA002494963A CA2494963A CA2494963A1 CA 2494963 A1 CA2494963 A1 CA 2494963A1 CA 002494963 A CA002494963 A CA 002494963A CA 2494963 A CA2494963 A CA 2494963A CA 2494963 A1 CA2494963 A1 CA 2494963A1
Authority
CA
Canada
Prior art keywords
epo
molecule
peptide
cell
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002494963A
Other languages
English (en)
Inventor
Matthew Baker
Francis J. Carr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2494963A1 publication Critical patent/CA2494963A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne l'identification d'épitopes associés aux lymphocytes T dans l'EPO humaine ainsi que des peptides d'épitopes de lymphocytes T dérivés de l'EPO grâce auxquels il est possible de créer de nouveaux variants d'EPO modifiés à immunogénicité réduite.
CA002494963A 2002-08-09 2003-08-07 Epitopes de lymphocytes t dans l'erythropoietine Abandoned CA2494963A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02017914 2002-08-09
EP02017914.9 2002-08-09
PCT/EP2003/008725 WO2004018515A2 (fr) 2002-08-09 2003-08-07 Epitopes de lymphocytes t dans l'erythropoietine

Publications (1)

Publication Number Publication Date
CA2494963A1 true CA2494963A1 (fr) 2004-03-04

Family

ID=31896824

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002494963A Abandoned CA2494963A1 (fr) 2002-08-09 2003-08-07 Epitopes de lymphocytes t dans l'erythropoietine

Country Status (16)

Country Link
US (1) US20060035322A1 (fr)
EP (1) EP1527094B1 (fr)
JP (1) JP2006515161A (fr)
KR (1) KR20060003853A (fr)
CN (1) CN1675242A (fr)
AT (1) ATE401344T1 (fr)
AU (1) AU2003263201A1 (fr)
BR (1) BR0313135A (fr)
CA (1) CA2494963A1 (fr)
DE (1) DE60322225D1 (fr)
ES (1) ES2310684T3 (fr)
MX (1) MXPA05001452A (fr)
PL (1) PL372862A1 (fr)
RU (1) RU2005106841A (fr)
WO (1) WO2004018515A2 (fr)
ZA (1) ZA200501974B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022593A2 (fr) * 2002-09-09 2004-03-18 Nautilus Biotech Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
US20060073563A1 (en) * 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2377884A1 (fr) * 2005-05-10 2011-10-19 Neoloch Aps Peptides neuritogènes
EP2120998B1 (fr) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Polypeptides d'érythropoïétine modifiés et utilisation de ceux-ci dans des traitements
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
EP2268297A4 (fr) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Toxines modifiées
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
SG11201600294QA (en) * 2013-07-17 2016-02-26 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN106554395B (zh) * 2015-09-30 2019-08-16 天津药物研究院有限公司 一种长效促红细胞生成素模拟肽及其制备方法和应用
AR113091A1 (es) * 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
EP3964225A1 (fr) * 2020-09-04 2022-03-09 Dompe' Farmaceutici S.P.A. Peptides dotés d'une activité angiogénique
BR112023003865A2 (pt) * 2020-09-04 2024-03-12 Dompe Farm Spa Peptídeos dotados de atividade angiogênica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
EP1051432B1 (fr) * 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
CA2288341C (fr) * 1998-12-17 2005-01-04 Pfizer Products Inc. Erythropoietine dans le traitement de l'anemie chez les animaux domestiques et le betail
PL365671A1 (en) * 2000-09-08 2005-01-10 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
HUP0400703A3 (en) * 2001-02-06 2006-06-28 Merck Patent Gmbh Modified erythropoietin (epo) with reduced immunogenicity
WO2002069232A2 (fr) * 2001-02-19 2002-09-06 Merck Patent Gmbh Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite

Also Published As

Publication number Publication date
EP1527094A2 (fr) 2005-05-04
US20060035322A1 (en) 2006-02-16
EP1527094B1 (fr) 2008-07-16
WO2004018515A2 (fr) 2004-03-04
RU2005106841A (ru) 2005-10-27
CN1675242A (zh) 2005-09-28
MXPA05001452A (es) 2005-06-06
JP2006515161A (ja) 2006-05-25
ZA200501974B (en) 2006-03-29
AU2003263201A1 (en) 2004-03-11
KR20060003853A (ko) 2006-01-11
ATE401344T1 (de) 2008-08-15
DE60322225D1 (en) 2008-08-28
WO2004018515A3 (fr) 2004-06-03
ES2310684T3 (es) 2009-01-16
PL372862A1 (en) 2005-08-08
BR0313135A (pt) 2005-07-05

Similar Documents

Publication Publication Date Title
ZA200501974B (en) T-cell epitopes in erythropoietin
ZA200502273B (en) T-cell epitopes in staphylococcal enterotoxin B.
EP1427820A2 (fr) Facteur ix modifie
KR20230019859A (ko) 펩타이드 칵테일
KR20040103970A (ko) 변형된 펙터 ⅷ
US20050181459A1 (en) Method for mapping and eliminating T cell epitopes
CA2459138A1 (fr) Hormone de croissance humaine modifiee
CN107223133B (zh) 一种可溶的异质二聚t细胞受体及其制法和应用
KR20050010898A (ko) 감소된 면역원성을 갖는 개질 브리오딘 1
US20050074863A1 (en) T-cell epitodes in carboxypeptidase g2
EP1512004B1 (fr) Methode de cartographie et d'elimination des epitopes t
CN109306004B (zh) 骨保护素的s77突变体蛋白及其相关产品与应用
CN109306002B (zh) 骨保护素的n139突变体蛋白及其相关产品与应用
CN109306003B (zh) 骨保护素的突变体蛋白及其相关产品与应用
ZA200306931B (en) Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity.
AU2002331095A1 (en) Modified factor IX

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued